AngioDynamics Shares Drop Despite Better-Than-Expected Q1 Earnings
Despite reporting a narrower-than-expected loss in its fiscal first quarter, AngioDynamics (NASDAQ: ANGO) stock fell nearly 21% as of early Thursday. The medical device company reported a pro forma net loss of $0.04 per share on revenue of $80.9 million for Q1 2027 — both figures exceeded analyst expectations. However, the GAAP loss was significantly worse at $0.17 per share compared to forecasts and much higher than its prior-year performance. Investors were also unimpressed with AngioDynamics' modest year-over-year revenue growth of just 6.9%. Additionally, while the company announced a leadership change — naming Eric Honroth as CEO after Jim Clemmer's departure — this did little to reassure investors given the firm’s ongoing financial struggles. AngioDynamics has not been profitable since 2020 and is projected by analysts to remain unprofitable until at least 2029. The company guided for full-year revenue of $336 million to $341 million, with pro forma losses expected between $0.24 and $0.29 per share.
Tickers: $ANGO
Topics: financial_performance leadership_change medical_devices